Annual Accounts Receivable
$17.47 M
+$689.00 K+4.10%
31 December 2023
Summary:
Theravance Biopharma annual accounts receivable is currently $17.47 million, with the most recent change of +$689.00 thousand (+4.10%) on 31 December 2023. During the last 3 years, it has risen by +$3.41 million (+24.24%). TBPH annual accounts receivable is now -52.97% below its all-time high of $37.15 million, reached on 31 December 2015.TBPH Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$16.84 M
+$2.55 M+17.81%
30 September 2024
Summary:
Theravance Biopharma quarterly accounts receivable is currently $16.84 million, with the most recent change of +$2.55 million (+17.81%) on 30 September 2024. Over the past year, it has dropped by -$629.00 thousand (-3.60%). TBPH quarterly accounts receivable is now -56.88% below its all-time high of $39.06 million, reached on 31 March 2016.TBPH Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TBPH Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -3.6% |
| 3 y3 years | +24.2% | +19.8% |
| 5 y5 years | -20.6% | -23.4% |
TBPH Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +24.2% | -3.6% | +37.3% |
| 5 y | 5 years | -20.6% | +24.2% | -23.4% | +47.6% |
| alltime | all time | -53.0% | +1442.3% | -56.9% | >+9999.0% |
Theravance Biopharma Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $16.84 M(+17.8%) |
| June 2024 | - | $14.30 M(-2.5%) |
| Mar 2024 | - | $14.66 M(-16.1%) |
| Dec 2023 | $17.47 M(+4.1%) | $17.47 M(+2.4%) |
| Sept 2023 | - | $17.06 M(+8.0%) |
| June 2023 | - | $15.80 M(+28.7%) |
| Mar 2023 | - | $12.27 M(-26.9%) |
| Dec 2022 | $16.79 M(+19.3%) | $16.79 M(+18.9%) |
| Sept 2022 | - | $14.11 M(+13.0%) |
| June 2022 | - | $12.49 M(+1.7%) |
| Mar 2022 | - | $12.28 M(-12.7%) |
| Dec 2021 | $14.06 M(-11.4%) | $14.06 M(+0.5%) |
| Sept 2021 | - | $14.00 M(+14.6%) |
| June 2021 | - | $12.22 M(+2.6%) |
| Mar 2021 | - | $11.91 M(-24.9%) |
| Dec 2020 | $15.87 M(-27.9%) | $15.87 M(+28.0%) |
| Sept 2020 | - | $12.40 M(+8.6%) |
| June 2020 | - | $11.41 M(-26.0%) |
| Mar 2020 | - | $15.41 M(-29.9%) |
| Dec 2019 | $22.00 M | $22.00 M(+369.8%) |
| Sept 2019 | - | $4.68 M(+329.5%) |
| June 2019 | - | $1.09 M(-86.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2019 | - | $7.94 M(-25.6%) |
| Dec 2018 | $10.67 M(+14.0%) | $10.67 M(+54.0%) |
| Sept 2018 | - | $6.93 M(-5.0%) |
| June 2018 | - | $7.30 M(+51.5%) |
| Mar 2018 | - | $4.82 M(-48.5%) |
| Dec 2017 | $9.36 M(-3.7%) | $9.36 M(-28.7%) |
| Sept 2017 | - | $13.12 M(+96.9%) |
| June 2017 | - | $6.66 M(-24.9%) |
| Mar 2017 | - | $8.87 M(-8.7%) |
| Dec 2016 | $9.72 M(-73.8%) | $9.72 M(-58.8%) |
| Sept 2016 | - | $23.59 M(-36.1%) |
| June 2016 | - | $36.94 M(-5.4%) |
| Mar 2016 | - | $39.06 M(+5.1%) |
| Dec 2015 | $37.15 M(+1645.1%) | $37.15 M(+81.9%) |
| Sept 2015 | - | $20.42 M(-22.3%) |
| June 2015 | - | $26.29 M(+30.0%) |
| Mar 2015 | - | $20.23 M(+850.0%) |
| Dec 2014 | $2.13 M(+87.9%) | $2.13 M(+418.0%) |
| Sept 2014 | - | $411.00 K(+346.7%) |
| June 2014 | - | $92.00 K(-1.1%) |
| Mar 2014 | - | $93.00 K(-91.8%) |
| Dec 2013 | $1.13 M | $1.13 M |
FAQ
- What is Theravance Biopharma annual accounts receivable?
- What is the all time high annual accounts receivable for Theravance Biopharma?
- What is Theravance Biopharma quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Theravance Biopharma?
- What is Theravance Biopharma quarterly accounts receivable year-on-year change?
What is Theravance Biopharma annual accounts receivable?
The current annual accounts receivable of TBPH is $17.47 M
What is the all time high annual accounts receivable for Theravance Biopharma?
Theravance Biopharma all-time high annual accounts receivable is $37.15 M
What is Theravance Biopharma quarterly accounts receivable?
The current quarterly accounts receivable of TBPH is $16.84 M
What is the all time high quarterly accounts receivable for Theravance Biopharma?
Theravance Biopharma all-time high quarterly accounts receivable is $39.06 M
What is Theravance Biopharma quarterly accounts receivable year-on-year change?
Over the past year, TBPH quarterly accounts receivable has changed by -$629.00 K (-3.60%)